(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 2.29% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Novartis Ag's revenue in 2025 is $56,372,000,000.On average, 26 Wall Street analysts forecast NVS's revenue for 2025 to be $108,959,598,000,000, with the lowest NVS revenue forecast at $102,673,134,000,000, and the highest NVS revenue forecast at $115,985,646,000,000. On average, 26 Wall Street analysts forecast NVS's revenue for 2026 to be $111,892,896,000,000, with the lowest NVS revenue forecast at $102,272,526,000,000, and the highest NVS revenue forecast at $118,863,090,000,000.
In 2027, NVS is forecast to generate $116,524,926,000,000 in revenue, with the lowest revenue forecast at $97,582,716,000,000 and the highest revenue forecast at $126,058,626,000,000.